Proteome-wide assessment of therapeutic candidate antibodies

Selecting the right therapeutic candidate antibody requires knowing what it binds to, including all off-target reactivities. This brochure shows how MIPSA (Molecular Indexing of Proteins by Self-Assembly) enables whole-proteome antigen libraries for unbiased, simultaneous profiling of on- and off-target mAb binding across represented human-protein targets, and how HuSIGHT applies that capability by bringing complementary full-length-protein and peptide libraries into a single MIPSA workflow. Those two antigen formats cover >353,000 overlapping peptide tiles across the full human proteome and >15,000 full-length human proteins, giving complementary views of linear and conformational epitopes. A worked example follows: an Infinity Bio internal MIPSA screen of a purified anti-p53 mAb, with binding signals measured across a 1:3 antibody concentration series, showing concentration-dependent intended-target and off-target binding under the conditions tested. A broader binding profile can inform candidate selection.

Read or download to see:

• How MIPSA whole-proteome antigen libraries make on- and off-target mAb binding measurable simultaneously across represented human-protein targets.
• The two HuSIGHT antigen formats: >353,000 overlapping peptide tiles and >15,000 full-length human proteins, for linear and conformational epitopes.
• What the example screen shows: concentration-dependent target and off-target binding for a purified anti-p53 mAb under the conditions tested.
• The three decisions it informs: catch potential off-target effects, rank mAbs by reactivity breadth and selectivity, characterize possible binders.